InvestSMART

Telix Pharmaceuticals Limited (ASX: TLX) - Announcements

Current share price for TLX : $15.060 0.2 (1.35%)+

ASX company news and announcements for Telix Pharmaceuticals Limited (TLX) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All Telix Pharmaceuticals Limited (TLX) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than Telix Pharmaceuticals Limited (TLX), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for Telix Pharmaceuticals Limited (TLX)

Search all Announcements
Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
$5,070 Application for quotation of securities - TLX 31 Jan 2025 8:43AM $28.810 $14.920 fallen by 48.21%
$5,070 Notification regarding unquoted securities - TLX 31 Jan 2025 8:38AM $28.810 $14.920 fallen by 48.21%
$5,070 Cleansing Notice 31 Jan 2025 8:37AM $28.810 $14.920 fallen by 48.21%
$5,070 Application for quotation of securities - TLX 31 Jan 2025 8:35AM $28.810 $14.920 fallen by 48.21%
$5,070 Telix Completes Acquisition of Tx Assets, Biologics Platform 31 Jan 2025 8:31AM $28.810 $14.920 fallen by 48.21%
$5,070 Telix Completes Acquisition of RLS (USA) Inc 28 Jan 2025 8:27AM $27.530 $14.920 fallen by 45.80%
$5,070 Illuccix Receives European Approval 17 Jan 2025 8:23AM $25.800 $14.920 fallen by 42.17%
$5,070 Telix JP Morgan Healthcare Conference 2025 Presentation 13 Jan 2025 5:11PM $24.020 $14.920 fallen by 37.89%
$5,070 Telix Exceeds FY24 Guidance with US$142M Q4 Revenue 13 Jan 2025 5:10PM $24.020 $14.920 fallen by 37.89%
$5,070 Proposed issue of securities - TLX 13 Jan 2025 8:32AM $23.990 $14.920 fallen by 37.81%
$5,070 Presentation to Accompany Biologics Platform Acquisition 13 Jan 2025 8:25AM $23.990 $14.920 fallen by 37.81%
$5,070 TLX to Acquire Next-Gen Therapeutics and Biologics Platform 13 Jan 2025 8:24AM $23.990 $14.920 fallen by 37.81%
$5,070 Notification of cessation of securities - TLX 9 Jan 2025 8:20AM $24.840 $14.920 fallen by 39.94%
$5,070 Managing Director and Group CEO Remuneration Update 30 Dec 2024 8:24AM $24.950 $14.920 fallen by 40.20%
$5,070 Telix Files TLX250-CDx (Zircaix) BLA for Kidney Imaging 30 Dec 2024 8:24AM $24.950 $14.920 fallen by 40.20%
$5,070 Securities Dealing Policy - Updated 13 Dec 2024 8:23AM $24.110 $14.920 fallen by 38.12%
$5,070 Notification regarding unquoted securities - TLX 28 Nov 2024 8:29AM $23.360 $14.920 fallen by 36.13%
$5,070 Application for quotation of securities - TLX 28 Nov 2024 8:27AM $23.360 $14.920 fallen by 36.13%
$5,070 Presentation to Accompany FAP-Targeting Acquisition 19 Nov 2024 8:22AM $22.780 $14.920 fallen by 34.50%
$5,070 Telix Adds FAP-Targeting Theranostic Candidates to Pipeline 19 Nov 2024 8:22AM $22.780 $14.920 fallen by 34.50%
$5,070 Securities Dealing Policy - Updated 14 Nov 2024 8:25AM $22.980 $14.920 fallen by 35.07%
$5,070 Telix ADSs Commence Trading on Nasdaq 14 Nov 2024 8:24AM $22.980 $14.920 fallen by 35.07%
$5,070 CMS payment improvement decision for radiopharma diagnostics 4 Nov 2024 8:37AM $21.450 $14.920 fallen by 30.44%
$5,070 FDA accepts NDA and grants priority review for Pixclara 24 Oct 2024 8:25AM $21.110 $14.920 fallen by 29.32%
$5,070 Pending Release of Shares from Voluntary Escrow 23 Oct 2024 8:22AM $21.020 $14.920 fallen by 29.02%

201 - 225 of 946 results

Page 9 of 38

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.